EUVIMEDEUVIMED entdecken
Crossref

Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer

Amin H Nassar iD, Elias Bou Farhat iD, Hassan Abushukair, Michel Alchoueriy, Samer Salem iD, Marc Machaalani iD, Elio Adib iD, Elizabeth P Henske, Priyanka Babu iD, Toni K Choueiri iD, Mehrdad Rakaee iD, Lill-Tove Rasmussen Busund iD und 12 weitere

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djaf344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Amin H Nassar und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Yale Cancer Center, New Haven, CT, United States. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Immunoconjugates, Antineoplastic Agents, Immunological. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Institution for Trials, SWOG Hope Foundation, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab deruxtecan (T-DXd) has transformed the treatment paradigm for HER2-expressing breast cancer, including HER2-low disease. However, biomarkers associated with T-DXd activity remain poorly defined. We conducted a comprehensive analysis of clinical, genomic, and immune correlates of T-DXd outcomes to identify molecular determinants of therapeutic benefit and resistance.

Methods

We retrospectively analyzed 2 independent cohorts of patients with advanced breast cancer treated with T-DXd at Dana-Farber Cancer Institute and Yale Cancer Center between 2018 and 2024. We included patients with ≥2 tumor blocks with HER2 immunohistochemistry (IHC) assessments prior to T-DXd. Clinical data on 524 patients were manually reviewed, and genomic profiling and immune microenvironment assessments were performed on a subset of patients. Multivariable Cox proportional hazards models evaluated associations between molecular features and overall survival (OS) and time to next treatment (TTNT).

Results

Among 524 patients, HER2 IHC discordance between sequential tumor biopsies was observed in 20% of patients and was independently associated with significantly worse OS (hazard ratio [HR] = 0.67; P = .012) and TTNT (HR = 0.65; P = .002), resembling outcomes seen in HER2 0 tumors. Genomic analysis revealed that PTEN mutations correlated with inferior TTNT (HR = 2.2; q = 0.068), whereas ERBB2 amplifications predicted improved OS and TTNT. An inflamed tumor microenvironment determined by digital pathology was associated with significantly poorer TTNT outcomes (median TTNT = 5.5 months) compared with immune-desert phenotypes (median OS = 9.6 months, P = .03).

Conclusions

This study identifies HER2 IHC discordance and specific genomic and immune features as prognostic biomarkers of T-DXd efficacy. These findings warrant prospective validation and may inform biomarker-driven strategies to optimize T-DXd therapy in HER2-expressing malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTrastuzumabImmunoconjugatesAntineoplastic Agents, ImmunologicalHumansFemaleErb-b2 Receptor Tyrosine KinasesMiddle AgedRetrospective StudiesTumor MicroenvironmentAgedBiomarkers, TumorAdultPTEN PhosphohydrolaseCamptothecin

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesERBB2 protein, humantrastuzumab deruxtecanBiomarkers, TumorImmunoconjugatesAntineoplastic Agents, ImmunologicalPTEN PhosphohydrolasePTEN protein, humanCamptothecin

Autor:innen und Institutionen

  • Division of Medical Oncology, Yale Cancer Center, New Haven, CT, United States.
  • Division of Pulmonary Medicine, Brigham and Women's Hospital, Boston, MA, United States.
  • Division of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
  • Department of Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
  • Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Amin H Nassar, Elias Bou Farhat, Samer Salem, Marc Machaalani, Elio Adib, Priyanka Babu, Toni K Choueiri, Mehrdad Rakaee, Lill-Tove Rasmussen Busund, Yamato Takabe, Shun-Fat Lau, Abdul Rafeh Naqash, Caroline Jansen, Xiao Wang, Paolo Tarantino, Ann H Partridge, Sara M Tolaney, David J Kwiatkowski, Eric P Winer

Förderung

  • Institution for Trials
  • SWOG Hope Foundation
  • AstraZeneca

Zitieren

APA

Nassar, A. H., Bou Farhat, E., Abushukair, H., Alchoueriy, M., Salem, S., Machaalani, M., Adib, E., Henske, E. P., Babu, P., Choueiri, T. K., Rakaee, M., Busund, L. R., Takabe, Y., Lau, S. F., Rall, K., Naqash, A. R., Jansen, C., Wang, X., Challa, P., …, & Winer, E. P. (2025). Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf344

Vancouver

Nassar AH, Bou Farhat E, Abushukair H, Alchoueriy M, Salem S, Machaalani M, et al. Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf344

BibTeX
@article{Nassar2025,
  author = {Nassar, Amin H and Bou Farhat, Elias and Abushukair, Hassan and Alchoueriy, Michel and Salem, Samer and Machaalani, Marc and Adib, Elio and Henske, Elizabeth P and Babu, Priyanka and Choueiri, Toni K and Rakaee, Mehrdad and Busund, Lill-Tove Rasmussen and Takabe, Yamato and Lau, Shun-Fat and Rall, Kerri and Naqash, Abdul Rafeh and Jansen, Caroline and Wang, Xiao and Challa, Pavan and Tarantino, Paolo and Partridge, Ann H and Tolaney, Sara M and Kwiatkowski, David J and Winer, Eric P},
  title = {Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djaf344}
}
Kostenlos starten →